Mevion Medical Systems

Mevion Medical Systems delivered its Mevion S250 proton therapy superconducting synchrocyclotron accelerator to the physician-owned proton therapy center at First Coast Oncology in Jacksonville, Fla.

A patient with a rare type of cancer (chondrosarcoma) at the base of the skull has become the first person in the world to receive proton therapy using the Mevion S250 proton therapy system from Mevion Medical Systems Inc. of Littleton, Mass.

Mevion Medical Systems has delivered the superconducting synchrocyclotron accelerator for its Mevion S250 proton therapy system under installation at the Peggy and Charles Stephenson Cancer Center at the University of Oklahoma.

Mevion Medical Systems announced the delivery of its fifth TriNiobium Core proton accelerator, the powerful proton source that is at the center of the revolutionary Mevion S250 Proton Therapy System. This accelerator will be delivered early next year to First Coast Oncology in Jacksonville, Fla. All 2013 and early 2014 Mevion S250 deliveries are already in the manufacturing stage.

June 11, 2012 — Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced that it has received FDA 510(k) clearance for its Mevion S250 Proton Therapy System. The Mevion S250 is a first-of-its-kind proton therapy system that provides the same precise, non-invasive treatment advantages and capabilities of complex, large, and costly proton therapy systems but with higher patient throughput, a significantly reduced footprint, improved reliability, and lower implementation and operational costs.  The Mevion S250 delivers precise and intense proton beams that physicians can use to treat tumors and lesions or any other condition where radiotherapy is indicated.